Fish Oil

Summary

Fish Oil (CHEMBL3833369) is an approved unknown; indicated across 25 conditions including cardiovascular disorder and rheumatoid arthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 25 conditions
• Clinical trials: 136

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833369
Name	Fish Oil
Type	Unknown
Max phase	4

Also known as: B1782, Fish oil, FISH OIL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

25 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
obesity disorder	3	MONDO:0011122	EFO:0001073
coronary artery disorder	3	MONDO:0005010	EFO:0001645
intestinal disorder	3	MONDO:0005020	EFO:0009431
cholestasis	3	MONDO:0001751	MONDO:0001751
depressive disorder	3	MONDO:0002050	MONDO:0002050
asthma	3	MONDO:0004979	MONDO:0004979
epilepsy	2	MONDO:0005027	EFO:0000474
liver disorder	2	MONDO:0005154	EFO:0001421
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:0003095
chronic kidney disease	2	MONDO:0005300	EFO:0003884
social phobia	2	MONDO:0001247	EFO:1001917
fatty liver disease	2	MONDO:0004790	HP:0001397
major depressive disorder	2	MONDO:0002009	MONDO:0002009
neoplasm	2	MONDO:0005070	MONDO:0004992
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
diabetic neuropathy	1	MONDO:0006626	EFO:1000783
kidney disorder	0	MONDO:0005240	EFO:0003086
breast neoplasm	0	MONDO:0021100	MONDO:0007254

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 136.

Phase distribution

Phase	Trials
Not specified	82
PHASE2	18
PHASE4	13
PHASE1	7
PHASE3	6
EARLY_PHASE1	5
PHASE2/PHASE3	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06629103	PHASE4	ACTIVE_NOT_RECRUITING	A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA
NCT00232219	PHASE4	COMPLETED	Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion
NCT00232232	PHASE4	COMPLETED	Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
NCT00232245	PHASE4	COMPLETED	Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.
NCT00552084	PHASE4	COMPLETED	Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
NCT00592683	PHASE4	TERMINATED	Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents
NCT00867828	PHASE4	COMPLETED	Neptune Krill Oil (NKO™) in Early Stage Alzheimer’s Disease (MNEMOSYNE)
NCT01089231	PHASE4	COMPLETED	Effects of Omega-3 Fatty Acids on the Human Gene Expression
NCT01842191	PHASE4	COMPLETED	Efficacy of Fish Oil in Multiple Sclerosis
NCT02140788	PHASE4	TERMINATED	Effects of Metformin and Fish Oil on Treatment With Clozapine
NCT02387931	PHASE4	COMPLETED	Supplementation in Adolescent Girls With Endometriosis
NCT04687124	PHASE4	UNKNOWN	EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -
NCT04699760	PHASE4	COMPLETED	The Effects of n-3 LCPUFAs in Patients With Colorectal Cancer
NCT06074250	PHASE2/PHASE3	RECRUITING	Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
NCT00072982	PHASE3	UNKNOWN	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils
NCT00336908	PHASE2/PHASE3	COMPLETED	Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery
NCT00658476	PHASE3	COMPLETED	Omega-3 Fatty Acids for Treatment of Depression in Adolescents
NCT01565278	PHASE3	TERMINATED	Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
NCT01769092	PHASE2/PHASE3	TERMINATED	Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
NCT02271230	PHASE3	COMPLETED	Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure
NCT02939079	PHASE2/PHASE3	COMPLETED	Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
NCT04386577	PHASE3	UNKNOWN	Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL
NCT05613803	PHASE3	UNKNOWN	Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
NCT06279793	PHASE2	RECRUITING	Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
NCT07575438	PHASE2	NOT_YET_RECRUITING	Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults
NCT00076518	PHASE2	COMPLETED	The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
NCT00090402	PHASE1/PHASE2	COMPLETED	Fish Oil and Alpha Lipoic Acid in Treating Alzheimer’s Disease
NCT00655525	PHASE2	COMPLETED	Omega-3 Fatty Acid Administration in Dialysis Patients
NCT01145066	PHASE2	COMPLETED	Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
NCT01179971	PHASE2	COMPLETED	n-3 and n-6 Fatty Acids in Rheumatoid Arthritis
NCT01181882	PHASE2	COMPLETED	Fish Oil and Aspirin With Type 2 Diabetes
NCT01412216	PHASE2	TERMINATED	The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance
NCT01547910	PHASE2	COMPLETED	Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children
NCT01594983	PHASE2	COMPLETED	A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
NCT01933243	PHASE2	COMPLETED	Treatment of Anxiety and Anorexia Nervosa in Adolescents
NCT02021513	PHASE2	COMPLETED	Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus
NCT02089165	PHASE2	COMPLETED	Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.
NCT02628483	PHASE2	COMPLETED	A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil
NCT03077724	PHASE2	COMPLETED	Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study
NCT03742492	PHASE2	UNKNOWN	Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).